National Employer Selects Dario Cardiometabolic and GLP-1 Solutions to Improve Employee Health

New client will use Dario’s integrated approach to support long-term behavior change for employees living with diabetes, pre-diabetes, hypertension and those taking a GLP-1 medication

NEW YORK, December 5, 2023 — DarioHealth Corp. (Nasdaq: DRIO) (“Dario” or the “Company”), a leader in the global digital health market, announced today a new contract to provide cardiometabolic and GLP-1 solutions to a national employer (the “Employer”) beginning in January 2024.

The Employer, a national logistics company, selected Dario to deliver integrated support for employees living with diabetes, pre-diabetes, weight management and hypertension, while also providing a tailored experience for employees taking a GLP-1 medication. Dario combines intelligent technologies and expert human support with billions of data insights gathered from a decade of consumer engagement to deliver highly personalized experiences that keep people engaged over time for optimal results.

“GLP-1 medications are creating tremendous upheaval for employers and payers, and our new contract with the Employer is a great example of how Dario is helping employers address the growing and costly problem. Dario’s solutions have been proven, in prior studies, to deliver long-term behavior change with and without a GLP-1 medication to help employers like the Employer realize the full potential in health outcomes,” said Rick Anderson, President of Dario.